Angiomax

Angiomax is a brand name of bivalirudin, approved by the FDA in the following formulation(s):

ANGIOMAX (bivalirudin - injectable; intravenous)

• 
  Manufacturer: MEDICINES CO
  
  Approval date: December 15, 2000
  
  Strength(s): 250MG/VIAL ^[RLD]

Has a generic version of Angiomax been approved?

No. There is currently no therapeutically equivalent version of Angiomax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Angiomax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Inhibitors of thrombin
  Patent 5,196,404
  Issued: March 23, 1993
  Inventor(s): Maraganore; John M. & Fenton, II; John W. & Kline; Toni
  Assignee(s): Biogen, Inc.
  Health Research, Inc.
  This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.
  
  Patent expiration dates:
  
  
  • August 13, 2012
    
    ✓ 
    Patent use: INHIBITION OF THROMBIN IN A PATIENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • February 13, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations of bivalirudin and processes of making the same
  Patent 7,582,727
  Issued: September 1, 2009
  Inventor(s): Krishna; Gopal & Musso; Gary
  Assignee(s): The Medicinces Company
  Pharmaceutical batch(es) or pharmaceutical formulation(s) comprising bivalirudin as the active ingredient, and a method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s). The pharmaceutical batch(es) or pharmaceutical formulation(s) may have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6%. Also, the pharmaceutical batch(es) or pharmaceutical formulation(s) may have a reconstitution time that does not exceed about 42 seconds. The method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s) may comprise dissolving bivalirudin in a solvent to form a first solution, efficiently mixing a pH-adjusting solution with the first solution to form a second solution in which the pH-adjusting solution may comprise a pH-adjusting solution solvent, and removing the solvent and the pH-adjusting solution solvent from the second solution.
  
  Patent expiration dates:
  
  
  • July 27, 2028
    
    ✓ 
    Drug product
  
  
  
  • January 27, 2029
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations of bivalirudin and processes of making the same
  Patent 7,598,343
  Issued: October 6, 2009
  Inventor(s): Krishna; Gopal & Musso; Gary
  Assignee(s): The Medicines Company
  Pharmaceutical batch(es) or pharmaceutical formulation(s) comprising bivalirudin as the active ingredient, and a method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s). The pharmaceutical batch(es) or pharmaceutical formulation(s) may have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6%. Also, the pharmaceutical batch(es) or pharmaceutical formulation(s) may have a reconstitution time that does not exceed about 42 seconds. The method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s) may comprise dissolving bivalirudin in a solvent to form a first solution, efficiently mixing a pH-adjusting solution with the first solution to form a second solution in which the pH-adjusting solution may comprise a pH-adjusting solution solvent, and removing the solvent and the pH-adjusting solution solvent from the second solution.
  
  Patent expiration dates:
  
  
  • July 27, 2028
    
    ✓ 
    Drug product
  
  
  
  • January 27, 2029
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Angiomax Consumer Information (Wolters Kluwer)
• Angiomax Consumer Information (Cerner Multum)
• Angiomax Advanced Consumer Information (Micromedex)
• Angiomax AHFS DI Monographs (ASHP)
• Bivalirudin Consumer Information (Wolters Kluwer)
• Bivalirudin Consumer Information (Cerner Multum)
• Bivalirudin Intravenous Advanced Consumer Information (Micromedex)
• Bivalirudin AHFS DI Monographs (ASHP)